CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Rudolf WernerAlexander HaugChristian BuskeSimon HeideggerAnna L IllertFlorian BassermannPeter HerhausAndreas BuckJohannes DuellMax S ToppSabrina KrausHermann EinseleConstantin LapaMarkus RadererGeorg LenzStefan HabringerBastian von TresckowUlrich KellerPublished in: Nuklearmedizin. Nuclear medicine (2024)
C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.
Keyphrases
- pet ct
- cell migration
- high resolution
- clinical practice
- cancer therapy
- diffuse large b cell lymphoma
- positron emission tomography
- allogeneic hematopoietic stem cell transplantation
- stem cells
- deep learning
- bone marrow
- low dose
- risk assessment
- photodynamic therapy
- drug delivery
- binding protein
- young adults
- acute lymphoblastic leukemia
- climate change
- mass spectrometry
- smoking cessation
- combination therapy
- iron oxide